Evidence map›Paper›PMID 34331787›Full record

ReviewInternational journal of methods in psychiatric research2021

Benzodiazepine high-doses: The need for an accurate definition.

Jean-Marc Cloos, Christopher Y S Lim Cow, Valéry Bocquet

Abstract readReview
In one paragraph

Review in International journal of methods in psychiatric research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Benzodiazepine high-doses: The need for an accurate definition.International journal of methods in psychiatric research · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jean-Marc CloosDepartment of Psychiatry, Hôpitaux Robert Schuman, Luxembourg, Luxembourg.ORCID 0000-0002-7655-5155
Christopher Y S Lim CowDepartment of Psychiatry, Hôpitaux Robert Schuman, Luxembourg, Luxembourg.
Valéry BocquetDepartment of Public Health, Competence Centre in Methodology and Statistics, Luxembourg Institute of Health, Luxembourg.ORCID 0000-0002-3089-2877

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesA clear definition of what we understand of high-dose misuse or of a 'markedly increased dose' (as stated by the DSM-5) is important and past definitions may be inadequate. The aim of this review is to describe the different definitions used and to test these definitions for their accuracy.

methodsA narrative PubMed literature review was conducted based on articles published between 1 January 1990 and 31 December 2020 describing benzodiazepines (in MeSH Terms or MeSH Major Topic) and high-dose (or high-dosage). Specific definitions were applied to a population sample to show how definitions affect high-dose benzodiazepine prevalence.

resultsMultiples of an equivalent-diazepam dose or of the World Health Organization 'defined daily dosage' were used more frequently than the overstep of the recommended maximum therapeutic dosage as a cut-off point.

conclusionHigh-dose use is rare but the prevalence in the general population varies among studies, mainly due to different definitions, making both clinical and epidemiological comparisons between studies difficult. Defining a high-dose user as a person who takes at least a higher dose than the maximum usual therapeutic dose over a defined period of time therefore appears to be clinically more consistent.

Indexed as

BenzodiazepinesHumansPrevalenceBenzodiazepinesanxiolyticsbenzodiazepinehigh-dose usehypnoticslong-term use

Identifiers

PMID34331787
PMCPMC8633930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.